Literature DB >> 12598443

Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.

C Hvarfner1, A Hillarp, J Larsson.   

Abstract

AIMS: To investigate if the presence of factor V Leiden has an influence on the prognosis in central retinal vein occlusion (CRVO).
METHODS: 166 patients with CRVO were studied retrospectively. They were tested for factor V Leiden using DNA analysis. The presence of the mutation was studied in correlation with the development of neovascular complications 1 year after the thrombotic event.
RESULTS: 56 of 166 patients (34%) developed neovascular complications after 1 year. In the patients who had the studied mutation 11 of 20 (55%) had developed neovascular complications after 1 year, compared to 45 of 146 patients (31%) in the group without factor V Leiden (p=0.04).
CONCLUSION: The presence of factor V Leiden seems to enhance the risk of developing neovascular complications in CRVO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598443      PMCID: PMC1771539          DOI: 10.1136/bjo.87.3.305

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  32 in total

1.  Retinal vein occlusion and inherited conditions predisposing to thrombophilia.

Authors:  R Albisinni; A Coppola; M Loffredo; A M Cerbone; G Di Minno; G M Greco
Journal:  Thromb Haemost       Date:  1998-10       Impact factor: 5.249

2.  [1691 G to A mutation of the factor V gene: no association with thrombosis of the central retinal vein].

Authors:  O Raguenes; B Mercier; M Escoffre; L Traore; M T Blouch; A Robinet; J F Abgrall; C Ferec
Journal:  Presse Med       Date:  1996-03-16       Impact factor: 1.228

3.  Prevalence of factor V Leiden in young adults with retinal vein occlusion.

Authors:  T Linna; A Ylikorkala; K Kontula; P Puska; T Tervo
Journal:  Thromb Haemost       Date:  1997-01       Impact factor: 5.249

4.  Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.

Authors:  J L Gottlieb; J P Blice; B Mestichelli; B A Konkle; W E Benson
Journal:  Arch Ophthalmol       Date:  1998-05

5.  Activated protein C resistance in patients with central retinal vein occlusion.

Authors:  J Larsson; A Sellman; B Bauer
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

6.  Factor V Leiden, activated protein C resistance, and retinal vein occlusion.

Authors:  A P Ciardella; L A Yannuzzi; K B Freund; D DiMichele; M Nejat; J T De Rosa; J R Daly; L Sisco
Journal:  Retina       Date:  1998       Impact factor: 4.256

7.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

8.  Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University.

Authors:  A Hirota; H K Mishima; Y Kiuchi
Journal:  Ophthalmologica       Date:  1997       Impact factor: 3.250

9.  Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.

Authors:  S L Graham; I Goldberg; B Murray; P Beaumont; B H Chong
Journal:  Aust N Z J Ophthalmol       Date:  1996-08

10.  Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1996-05
View more
  1 in total

1.  Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales' disease by immunohistochemical analysis: a case report.

Authors:  Aditya Verma; Jyotirmay Biswas; Selvi Radhakrishnan; Angayarkanni Narayanasamy
Journal:  Int Ophthalmol       Date:  2010-01-05       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.